

Advanced Therapy Showcase in Tokyo #2

The Partnering Event in Tokyo Calls for Live-Streaming Presenters



Summary

Life Science Innovation Network Japan (LINK-J) boldly launched the partnering event series “Advanced Therapy Showcase in Tokyo (ATST)” with its first edition successfully held back in January 2021. Now we are pleased to announce that the second edition of the series, the ATST#2, is going to be held on Friday, January 28, 2022.

The ATST#2 features live-streaming company presentations and pre-arranged 1-on-1 business partnering Meetings. The event will be fully virtual.

Any entities or individuals engaged in the field of advanced therapy including but not limited to cell & gene therapy, regenerative medicine, nucleic acid therapy, etc., are encouraged to participate in this event to find suitable and relevant partner candidates for their business endeavors.

Event Outline

Date	Friday, January 28, 2022, JST
Format	Virtual
Program	Under construction
Official Language	English
Contact	atst@link-j.org
Sponsor Organizer	LINK-J
Registration/ Application	https://atst220128.peatix.com



Held in Combination with “The 6th Industry Academic Government Symposium on Regenerative Medicine”

Target Groups for Company Presenters

Product developers, novel technology providers, platform developers, and researchers who seek partners in Japan or elsewhere, and crave to excel in the field of advanced therapies such as:

- ✓ regenerative medicine and tissue engineering,
- ✓ cell therapy and gene-modified cell therapy,
- ✓ gene therapy (in vivo/ex vivo) and gene editing therapy,
- ✓ exosome-based therapy,
- ✓ nucleic acid medicine,

Registration & Application

	Registration tiers	Registration fee	Registration deadline
Live-streaming company presenters	<ul style="list-style-type: none">✓ Entitled to give a virtual live-streaming presentation for 20~25min (time is subject to change depending on the number of entries). <i>In case the number of applicants exceeds the capacity, the organizing committee may ask a certain number of applicants to wait for the next occasion.</i>✓ Entitled to one-on-one business meeting arrangements, and✓ Entitled to access the live-streaming presentations.	20,000JPY /organization 10,000JPY /LINK-J member <i>Discount rate (15,000 JPY/organization) will be applied for those who present the discount code, which will be given to supporting organizations to distribute among its members</i>	Friday, December 10, 2021, JST

General Attendees

We plan to open registration site for general attendees in November (free of charge). If you are interested in participating as a general attendee at this stage, give us a note at atst@link-j.org. You will be notified individually when the site opens.

* Registration/application website is <https://atst210128.peatix.com>

* Non-confidentiality : Any information disclosed in live-streaming presentations shall be regarded as non-confidential.

Summary on the Previous Edition

Company presentation speakers at the ATST#1

- BrainXell, Inc. ; Shouming Du (USA)
- Exopharm Ltd. ; Chris Baldwin, PhD (Australia)
- TerumoBCT, Inc. ; Jun Tanaka (Japan)
- Helixmith Co., Ltd. ; Sunyoung Kim, PhD (ROK)
- Eyestem Research Pvt. Ltd. ; Jogin Desai (India)
- CellProthera Pte. Ltd. Singapore ; Alexandre Civiére (Singapore)
- Biomaster Inc. ; Takuji Hasegawa (Japan)
- Fraunhofer Institute for Cell Therapy and Immunology (IZI) ; Thomas Tradler (Germany)
- Salipro Biotech AB ; Maria Knudsen, PhD (Sweden)
- PDC*line pharma SA ; Eric Halioua, MS, MBA (Belgium)
- TreeFrog Therapeutics SAS ; Maxime Feyeux, PhD (France)
- Glycostem Therapeutics B.V. ; Troels Jordansen (Netherlands)

On-demand exhibitors at the ATST#1

- Q-Gen Cell Therapeutics (Australia)
- Immusoft Corporation(USA)
- Nippon Boehringer Ingelheim Co., Ltd. (Japan)
- Biogelx Ltd. (UK)
- The Isthmus Foundation (USA)
- ORGANOIDSCIENCES Ltd. (ROK)
- Inner Resource, Inc. (Japan)

Participating companies at the ATST#1


4Bio Capital	CMPlus	Helixmith Co., Ltd.
ACCERISE, Inc.	Cyfuse Biomedical	Hitachi Global Life Solutions, Inc.
aceRNA Technologies, Co., Ltd.	Cytori Therapeutics Inc.	Hokkaido University
ActualEyes Inc.	D3 LLC	Ibaraki Prefectural Government
Ajinomoto Co., Inc.	Daiichi Sankyo Co., Ltd.	iBody inc.
Alliance for Regenerative Medicine (ARM)	Digital Garage, Inc.	Immusoft Corporation
ARTWORKS Inc.	DyDo Pharma, Inc.	Information Services International-
Asahi Kasei Pharma Corporation	Eil Inc.	Dentsu, Ltd.
Aspect Biosystems Ltd.	Eli Lilly	Inner Resource
Astellas Pharma Inc.	Elixirgen Scientific, Inc.	Inno BioScience Co., Ltd.
Axil Capital Advisors K.K.	ENEOS	Isthmus Foundation
Biogelx Ltd.	Eurotechnology Japan K.K.	Japan Agency for Medical Research and Development
Biomaster Inc.	Exopharm Ltd.	Japan Blood Products Organization
BioSket / BioWire	Eyestem Research Pvt. Ltd.	Japan External Trade Organization (JETRO)
BrainXell, Inc.	Forum for Innovative Regenerative Medicine (FIRM)	Japan Medical Publisher
Cambridge Consultants	Fraunhofer Institute for Cell Therapy and Immunology (IZI)	JCR Pharmaceuticals
Cardiff University	Frontier Management Inc.	JGC Holdings Corporation
Cell and Gene Therapy Catapult	Fuji Chemical Industries Co., Ltd.	Johnson and Johnson Innovation
CellGenTech, Inc.	Fujimi Venture Partners Ltd.	JPRO/Western University
Cellino	Fujinokuni Medical Castle Town	JSR Corporation
CellProthera Pte. Ltd. Singapore	Promotion Organization Pharma Valley Center	JW CreaGene
CellSeed Inc.	General Prognostics, Inc. (GPx)	
Century Medical, Inc.	Global Life Sciences Technologies Japan	
CHARTAE Consulting, LLC.	Glycostem Therapeutics B.V.	
Chugai Pharmaceutical Co., Ltd.		
City of Yokohama		
CMIC Holdings Co., Ltd.		

Participating companies at the ATST#1

KAHM Japan Ltd.	NEC Corp.	Shinsei Capital Partners, Ltd.
KAKEHASHI Inc.	NejoScience Co., Ltd.	Shirakawa Life Research
Kawasaki City	Nippon Boehringer Ingelheim Co.,Ltd	Showa Denko Materials Co., Ltd.
Keio University	Nippon Shinyaku Co., Ltd.	SIGMAXYZ Inc.
Kirin Holdings Company, Limited	Nobelpharma Co., Ltd.	SOUSEIKAI Global Clinical Research Center
Komazawa University	NOF Corporation	Spiber Inc.
Kowa Co., Ltd.	Organization for Small & Medium Enterprises and Regional Innovation, JAPAN	S-RACMO Co., Ltd.
Kuraray Co., Ltd.	ORGANOIDSCIENCES Ltd.	Sumitomo Dainippon Pharma Co., Ltd.
Kureha Corporation	Otsuka Pharmaceutical Co., Ltd.	Taiho Innovations, LLC
Kyowa Kirin Co., Ltd.	Otsuka Pharmaceutical Factory, Inc.	Takeda Pharmaceutical Co., Ltd.
Kyushu University Hospital	PDC*line pharma SA	Tanaka Kikinzoku Kogyo K.K.
Life Science Institute, Inc.	Perseus proteoimics, Inc.	Temari, Inc.
Marubeni Corporation	Pfizer Japan Inc.	TerumoBCT, Inc.
MATRIXOME, Inc.	Pharma Business Academy Ltd.	Tohoku University
Medical & Biological Laboratories Co., Ltd.	PuREC Co., Ltd.	Tokyo Medical and Dental University
MediGear International Corporation	Q-Gen Cell Therapeutics	TreeFrog Therapeutics SAS
MEDINET Co., Ltd.	Queen Mary University of London (QMUL)	U.S. Embassy, Tokyo
Megakaryon Corporation	Rainbow BioScience, LLC	University of Rochester Medical Center
Metcela Inc.	Remiges Ventures, KK	University of Yamanashi
miibio, Inc.	RICOH Co., Ltd.	VectorBuilder Japan
Mitsubishi Corporation	RIKEN (Institute of Physical and Chemical Research)	WillNet
Mitsubishi Research Institute	ROHTO Pharmaceutical Co., Ltd.	Xsphera Biosciences Inc.
Mitsubishi Tanabe Pharma Corporation	RoslinCT Ltd.	
Mitsui Chemicals, Inc.	Salipro Biotech AB	
Mizuho Bank, Ltd.	SanBio Co., Ltd.	
Mochida Pharmaceutical Co., Ltd.	Santen Pharmaceutical Co., Ltd.	
Modalis Therapeutics Corporation	ShiftZero K.K.	
Nagano Science Co., Ltd.	Shimadzu Corp.	
National Center for Child Health and Development		
National Institute of Health Sciences		

Backgrounds of attendees at the ATST#1

By Area



By Business Type

